after joining the study you provide written consent and undergo a baseline medical evaluation that includes a review of your health history, physical examination, and laboratory tests.

samples of blood and other tissues are collected at this time to establish reference values before receiving any study medication.

the study medication is given as an intravenous infusion.

the dose is 30,000,000 cells per kilogram of your body weight, delivered in a single infusion session.

the infusion is performed in a clinical setting by qualified staff.

following the infusion you are observed for several hours to monitor vital signs, any immediate reactions, and overall tolerance of the medication.

additional blood samples may be taken during this period to evaluate early responses.

you will attend follow‑up visits at week 1, week 4, week 12, and then every six months for the duration of the study.

at each visit blood and, when required, other tissue samples are collected to monitor for signs of malignancy related to insertional oncogenesis.

clinical assessments, including physical examinations and laboratory tests, are performed at each visit.

once a year you undergo a comprehensive evaluation that may include imaging studies, detailed blood analyses, and additional sample collections.

the purpose of these annual visits is to continue surveillance for any late‑appearing malignancies and to assess overall health.

the study is scheduled to end on 2035‑07‑31.

at the final visit a complete set of assessments and samples is obtained to determine the long‑term safety outcomes of the treatment.